Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy

Michaela Kuhlen, Kirsten Bleckmann, Anja Möricke, Martin Schrappe, Simon Vieth, Gabriele Escherich, Annika Bronsema, Annika Vonalt, Manon Queudeville, C. Michel Zwaan, Martin Ebinger, Klaus Michael Debatin, Thomas Klingebiel, Ewa Koscielniak, Claudia Rossig, Birgit Burkhardt, Reinhard Kolb, Cornelia Eckert, Arndt Borkhardt, Arend von StackelbergChristiane Chen-Santel

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

23 Citaten (Scopus)

Samenvatting

The prognosis in children with refractory or relapsed (r/r) T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL) is poor. Nelarabine (Ara-G) has successfully been used as salvage therapy in these children, but has been associated with significant, even fatal, neurotoxicities. We retrospectively analysed 52 patients with r/r T-ALL/T-LBL aged ≤19 years who were treated with Ara-G alone (n = 25) or in combination with cyclophosphamide and etoposide (n = 27). The majority of patients (45/52) received 1–2 cycles of Ara-G. Seventeen patients (32·7%) had refractory disease, 28 (53·8%) were in first relapse and 7 (13·5%) were in second relapse. A response to Ara-G was achieved in 20 patients and 15 (28·8%) were in remission at last follow-up. Twelve patients (23·1%) had neurotoxic adverse effects (neuro-AE) of any grade, of whom 7 (13·5%) developed neurotoxicity ≥ grade III. The most frequent neuro-AEs were peripheral motor neuropathy (19·2%), peripheral sensory neuropathy (11·5%) and seizures (9·6%). Three patients died of central neuro-AE after 1–2 cycles of combination therapy. Patients with neurotoxicity were significantly older (median 15·17 years) than those without (10·34 years, P = 0·017). No differences were observed between mono- and combination therapy concerning outcome and neuro-AE. The incidence of neuro-AE was not associated with concurrent intrathecal therapy or prior central nervous system irradiation.

Originele taal-2Engels
Pagina's (van-tot)272-283
Aantal pagina's12
TijdschriftBritish Journal of Haematology
Volume179
Nummer van het tijdschrift2
DOI's
StatusGepubliceerd - okt. 2017
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit